Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Zacks.com on MSN6d
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...
Investor's Business Daily on MSN11d
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest MoneymakerNovartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.
Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...
Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Novartis forecasts further profit and sales ... cholesterol treatment Leqvio and multiple sclerosis medicine Kesimpta--offset a one-percentage-point hit from generic competition.
Novartis has performed well in the previous ... Scemblix (chronic myeloid leukemia or CML), Pluvicto (prostate cancer), Leqvio (cholesterol) and Fabhalta (paroxysmal nocturnal hemoglobinuria ...
Last week, Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback